1,245
Participants
Start Date
October 31, 2005
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)
Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
Havrix™
Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
GSK Investigational Site, Taipei
GSK Investigational Site, Tao Yuan County
GSK Investigational Site, Bogotá
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Rostock
GSK Investigational Site, Bützow
GSK Investigational Site, Hamburg
GSK Investigational Site, Flensburg
GSK Investigational Site, Harrislee
GSK Investigational Site, Brunsbüttel
GSK Investigational Site, Husum
GSK Investigational Site, Niebüll
GSK Investigational Site, Wolfenbüttel
GSK Investigational Site, Bochum
GSK Investigational Site, Willich
GSK Investigational Site, Trier
GSK Investigational Site, Mannheim
GSK Investigational Site, Deggingen
GSK Investigational Site, Kehl
GSK Investigational Site, Ettenheim
GSK Investigational Site, Weilheim
GSK Investigational Site, Würzburg
GSK Investigational Site, Tauberbischofsheim
GSK Investigational Site, Weimar
GSK Investigational Site, Bogotá
GSK Investigational Site, Comayagüela
GSK Investigational Site, La Chorrera
Lead Sponsor
GlaxoSmithKline
INDUSTRY